SCHEMBL15965636

SCHEMBL15965636

Oc1ccc(O)c(/C=N/Nc2cccc3ccccc23)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 13/20 0.52
KMT2A Q03164 13/20 0.52
MAPT P10636 8/20 0.52
GAA P10253 7/20 0.52
SMN1; SMN2 Q16637 6/20 0.52
RAB9A P51151 6/20 0.52
HTT P42858 5/20 0.52
TDP1 Q9NUW8 4/20 0.52
HPGD P15428 3/20 0.52
ALDH1A1 P00352 3/20 0.52
NFKB1 P19838 2/20 0.52
NFKB2 Q00653 2/20 0.52
RELA Q04206 2/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
LMNA P02545 2/20 0.52
NPC1 O15118 6/20 0.49
KDM4E B2RXH2 4/20 0.49
MGAM O43451 1/20 0.47
SI P14410 1/20 0.47
MGAM2 Q2M2H8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6568237 0.76 KMT2A (0.77) MEN1KMT2AMAPTGAASMN1; SMN2
SCHEMBL6568234 0.76 KMT2A (0.77) MEN1KMT2AMAPTGAASMN1; SMN2
SCHEMBL15722733 0.76 MPO (0.64) MEN1KMT2AMAPTGAASMN1; SMN2
SCHEMBL15965638 0.73 KMT2A (0.60) MEN1KMT2AMAPTGAASMN1; SMN2
SCHEMBL11419356 0.73 GAA (0.66) MEN1KMT2AMAPTGAASMN1; SMN2
SCHEMBL11433940 0.72 NOX1 (0.53) MEN1KMT2AMAPTGAASMN1; SMN2
SCHEMBL5364167 0.72 MAPT (0.71) MEN1KMT2AMAPTGAASMN1; SMN2
SCHEMBL5364159 0.72 MAPT (0.71) MEN1KMT2AMAPTGAASMN1; SMN2
SCHEMBL16476573 0.71 CRHBP (0.51) MEN1KMT2AMAPTGAASMN1; SMN2
SCHEMBL10064203 0.70 KDM4E (0.61) MEN1KMT2AMAPTGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9447059-B2 Intermediate for manufacture of polymerizable compound and process for manufacture thereof ZEON CORPORATION (JP) 2016-09-20 US disclosed
US-9447059-B2 Intermediate for manufacture of polymerizable compound and process for manufacture thereof ZEON CORPORATION (JP) 2016-09-20 US disclosed
US-20140235857-A1 INTERMEDIATE FOR MANUFACTURE OF POLYMERIZABLE COMPOUND AND PROCESS FOR MANUFACTURE THEREOF ZEON CORPORATION (JP) 2014-08-21 US disclosed
US-20140235857-A1 INTERMEDIATE FOR MANUFACTURE OF POLYMERIZABLE COMPOUND AND PROCESS FOR MANUFACTURE THEREOF ZEON CORPORATION (JP) 2014-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140235857-A1 INTERMEDIATE FOR MANUFACTURE OF POLYMERIZABLE COMPOUND AND PROCESS FOR MANUFACTURE THEREOF COASY, CYBA, CYP1B1 MEN1 3701/4885KMT2A 368/4885MAPT 2005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.